Journal
DRUG DISCOVERY TODAY
Volume 27, Issue 7, Pages 1789-1795Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2022.01.013
Keywords
Rare and intractable diseases; Ontology; Clinical trials; Drug target genes; Drug repositioning; Drug repurposing
Categories
Funding
- Japan Society for the Promotion of Science (JSPS) [20K12056]
Ask authors/readers for more resources
Drug repositioning is an effective approach for developing drugs for rare and intractable diseases. Preparation of ontology is crucial for drug development in these diseases, as disease names are inconsistently used worldwide. Ontology-based analysis of clinical trial data has revealed the active occurrence of drug repositioning in rare and intractable diseases, with drugs and their target genes playing a key role in exploring repositionable drugs.
Drug repositioning (DR) is an effective way for developing drugs for rare and intractable diseases (RIDs). Preparation of the ontology is essential for drug development in RIDs, in which disease names have been inconsistently used worldwide. Ontology-based analysis of clinical trial data revealed that DR occurs actively in RIDs. Drugs and their target genes are keys to explore repositionable drugs, because shared target genes between diseases indicate a common mechanism of drug action. This approach visualizes a DR landscape that facilitates drug development. Here, we review the current situation of ontology in RIDs, the trends in drug development, and an efficient strategy for DR based on drug target gene information.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available